Ann Lab Med.  2015 Jan;35(1):159-161. 10.3343/alm.2015.35.1.159.

Two Cases of Acute Lymphoblastic Leukemia with an e1a3 BCR-ABL1 Fusion Transcript

• Shin SY
• Cho JH
• Kim HJ
• Jang JH
• Lee ST
• Kim SH

• KMID: 2363168
• DOI: http://doi.org/10.3343/alm.2015.35.1.159

Abstract

No abstract available.

MeSH Terms

Antineoplastic Agents/therapeutic use
Base Sequence
DNA/chemistry/genetics/metabolism
DNA Mutational Analysis
Fusion Proteins, bcr-abl/*genetics
Genotype
Humans
Imatinib Mesylate/therapeutic use
Karyotyping
Male
Multiplex Polymerase Chain Reaction
Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/drug therapy/*genetics
Antineoplastic Agents
DNA
Fusion Proteins, bcr-abl
Imatinib Mesylate

Figure

• 

  Fig. 1 Multiplex reverse transcriptase (RT)-PCR with sequencing analysis and BCR-ABL1 gene mutation study for imatinib resistance. Multiplex RT-PCR and sequencing analysis revealed the e1a3 BCR-ABL1 fusion transcript in patient 1 (A, B) and patient 2 (C, D). BCR-ABL1 gene mutation study was performed for imatinib resistance in patient 2 (E, F). The mutation was detected 12 months after treatment. The 736th nucleotide (empty arrow) of the ABL1 gene was changed from G to A [NM_005157.4: c.763G>A (p.Glu255Lys)].

Reference

1. Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K. A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. Int J Hematol. 2008; 87:184–188. PMID: 18253707.

2. Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007; 92:1699–1702. PMID: 18055996.

3. Soekarman D, van Denderen J, Hoefsloot L, Moret M, Meeuwsen T, van Baal J, et al. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 1990; 4:397–403. PMID: 2193202.

4. Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia. 1994; 8:1696–1702. PMID: 7934165.

5. Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol. 2000; 111:1109–1111. PMID: 11167748.

6. Roman J, Jimenez A, Barrios M, Castillejo JA, Maldonado J, Torres A. E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol. 2001; 114:635–637. PMID: 11552990.

7. Schultheis B, Wang L, Clark RE, Melo JV. BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia. 2003; 17:2054–2055. PMID: 14513059.

8. Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res. 2008; 32:579–585. PMID: 17928051.

9. Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006; 148:249–256. PMID: 17145570.

10. Kim HJ, Oh HJ, Lee JW, Jang PS, Chung NG, Kim M, et al. Utility of a multiplex reverse transcriptase-polymerase chain reaction assay (HemaVision) in the evaluation of genetic abnormalities in Korean children with acute leukemia: a single institution study. Korean J Pediatr. 2013; 56:247–253. PMID: 23807891.